Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Review Article

Biosafety and product release testing issues relevant to replication-competent oncolytic viruses

Cancer Gene Therapy volume 9, pages 1056–1061 (2002)Cite this article

Abstract

Replication competent oncolytic viruses, like other biological products, are at risk from contamination by bacteria, fungi, mycoplasma and viruses that must be eliminated from the final product. This article reviews the regulatory guidance for the manufacture and testing for oncolytic virus products. A testing strategy covering the testing of cell lines, virus banks, virus harvests and purified product is described.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Melnick JL, Tinebaugh S . Excretion of vauloating SV40 virus (Papova virus group) after ingestion as a contaminant of oral poliovaccine Proc Soc Exp Biol Med 1962 109: 965–968

    Article  CAS  Google Scholar 

  2. Uphoff CC, Drexler HG . Comparative PCR analysis for detection of mycoplasma infections in continuous cell lines In Vitro Cell Dev Biol Anim 2002 38: 79–85

    Article  CAS  Google Scholar 

  3. Nettleton PF, Rweyemanu MM . The association of calf serum with the contamination of BHK21 clone 13 suspension cells by a parvovirus serologically related to the minute virus of mice (MVM) Arch Virol 1980 64: 359–374

    Article  CAS  Google Scholar 

  4. Rabenau H, Ohlinger V, Anderson J et al. Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV) Biologicals 1993 21: 207–214

    Article  CAS  Google Scholar 

  5. Bolin SR, Ridpath JF, Black J et al. Survey of cell lines in the American Type Culture Collection for bovine viral diarrhoea virus J Virol Methods 1994 48: 211–221

    Article  CAS  Google Scholar 

  6. Garnick RL . Experience with viral contamination in cell culture Dev Biol Stand 1996 49–56

  7. Giangaspero M, Vacirca G, Harasawa R et al. Genotypes of pestivirus RNA detected in live virus vaccines for human use J Vet Med Sci 2001 63: 723–733

    Article  CAS  Google Scholar 

  8. Croghan DL, Matchett A, Koski TA . Isolation of porcine parvovirus from commercial trypsin Appl Microbiol 1973 26: 431–433

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Marcus-Sekura CJ . Introduction to the issues: detection of retroviruses and associated risks Dev Biol Stand 1992 76: 137–140

    CAS  PubMed  Google Scholar 

  10. Anderson KP, Low MA, Lie YS et al. Endogenous origin of defective retrovirus-like particles from a recombinant Chinese hamster ovary cell line Virology 1991 181: 305–311

    Article  CAS  Google Scholar 

  11. Robertson JS, Nicolson C, Riley AM et al. Assessing the significance of reverse transcriptase activity in chick cell–derived vaccines Biologicals 1997 25: 403–414

    Article  CAS  Google Scholar 

  12. Weissmahr RN, Schupbach J, Boni J . Reverse transcriptase activity in chicken supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA J Virol 1997 71: 3005–3012

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Moore WA . Experience in cell line testing Dev Biol Stand 1992 76: 51–56

    CAS  PubMed  Google Scholar 

  14. Hakku B, Halton DM, Mally M et al. Cell characterisation by use of multiple genetic markers In: Acton RT, Lynn JD, eds Eukaryotic Cell Cultures New York, NY: Plenum 1984 13–31

    Chapter  Google Scholar 

  15. European Medicines Evaluation Agency. Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products. London April 2001 CPMP/BWP/3088/99

  16. USA Food and Drug Administration. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. Washington, DC March 1998

  17. USA Food and Drug Administration. Points to Consider in the Characterisation of Cell Lines Used to Produce Biologicals. Washington, DC August 1993

  18. International Committee for Harmonisation. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human and animal origin USA Fed Regist 1998 63: 51074–51084

  19. International Committee for Harmonisation. Guidance on quality of biotechnological/biological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products USA Fed Regist 1998 63: 50244–50249

  20. Medicines Control Agency. EC Guide to Good Manufacturing Practice. Rules and Guidance for Pharmaceutical Manufacturers and Distributors London: The Stationery Office 1997 43–202

  21. European Commission. EC Guide to Good Manufacturing Practice: Annex 13. Manufacture of Investigational Medicinal Products. Brussels November 2001 Draft 1

  22. European Commission. Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use Off J Eur Communities 2001 121: 34–44

  23. European Medicines Evaluation Agency. Note for Guidance on the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and Veterinary Medicinal Products. London 2001 EMEA/410/01

  24. European Directorate for the Quality of Medicines. Cell substrates for the production of vaccines for human use In European Pharmacopoeia 4th ed Strasbourg: Council of Europe 2002 415–418

  25. European Directorate for the Quality of Medicines. Tests for extraneous agents in viral vaccines for human use In European Pharmacopoeia 4th ed Strasbourg: Council of Europe 2002 148–149

  26. Liebermann H, Mentel R . Quantification of adenovirus particles J Virol Methods 1994 50: 281–291

    Article  CAS  Google Scholar 

  27. Stacey G, Bolton B, Doyle A, Griffiths B . DNA fingerprinting — a valuable new technique for the characterisation of cell lines Cytotechnology 1992 9: 211–216

    Article  CAS  Google Scholar 

  28. Hane B, Tummler M, Jager K et al. Differences in DNA fingerprints of continuous leukaemia–lymphoma cell lines from different sources Leukemia 1992 6: 1129–1133

    CAS  PubMed  Google Scholar 

  29. Nims RW, Shoemaker AP, Bauernschub MA et al. Sensitivity of isoenzyme analysis for the detection of interspecies cell line cross-contamination In Vitro Cell Dev Biol Anim 1998 34: 35–39

    Article  CAS  Google Scholar 

  30. Parenteral Drug Association. Technical report no. 22. Process simulation testing for aseptically filled products PDA J Pharm Sci Technol 1996 50: S1

  31. Parenteral Drug Association. Technical report no. 36. Current practices in the validation of aseptic processing — 2001 PDA J Pharm Sci Technol 2002 56: TR36

  32. European Medicines Evaluation Agency. Draft Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products. London April 2002 CPMP/BWP/793/02

  33. US Code of Federal Regulations. Requirements for Ingredients of Animal Origin Used for Production of Biologics. United States Government Printing Office. Washington, DC 2002 9 CFR 113.53

  34. Hardegree MC . Letter to Industry US Food and Drug Administration, Division of Vaccines and Related Products Applications. Washington, DC December 14, 1998

    Google Scholar 

  35. European Directorate for the Quality of Medicines. Poliomyelitis vaccine (inactivated) In European Pharmacopoeia 4th ed Strasbourg: Council of Europe 2002 2206–2209

  36. Lakshminarayanan S, Kodihalli S, Herrick S et al. Scalable purification of Reolysin for cancer therapy In Proceedings of 5th Annual Meeting American Society of Gene Therapy 2002 945

  37. Huyghe BG, Liu X, Sutjipto S et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography Hum Gene Ther 1995 6: 1403–1416

    Article  CAS  Google Scholar 

  38. European Directorate for the Quality of Medicines. Biological tests, sterility In European Pharmacopoeia 4th ed Strasbourg: Council of Europe 2002 123–127

  39. European Directorate for the Quality of Medicines. Biological tests; bacterial endotoxins In European Pharmacopoeia 4th ed Strasbourg: Council of Europe 2002 140–147

Download references

Author information

Authors and Affiliations

  1. BioReliance, Innovation Park, Stirling, UK

    Martin Wisher

Authors
  1. Martin Wisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Wisher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wisher, M. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Ther 9, 1056–1061 (2002). https://doi.org/10.1038/sj.cgt.7700536

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700536

Keywords

This article is cited by

Search

Advanced search

Quick links